Mirum Pharmaceuticals Says Volixibat Phase IIb VISTAS Hits Endpoint, Cuts PSC Itch vs Placebo

Mirum Pharmaceuticals Says Volixibat Phase IIb VISTAS Hits Endpoint, Cuts PSC Itch vs Placebo

Mirum Pharmaceuticals (NASDAQ:MIRM) said its Phase IIb VISTAS study of volixibat in patients with primary sclerosing cholangitis (PSC) met its primary endpoint, showing a statistically significant reduction in cholestatic pruritus compared with placebo, according to executives on the company’s busin

Mirum Stock Jumps After Volixibat Trial Win Puts First PSC Itch Drug Within Reach

Mirum Pharmaceuticals said its drug volixibat met the main goal in a 158-patient Phase 2b trial for primary sclerosing cholangitis, reducing itch scores more than placebo. Shares rose about 9% after the announcement. The company plans a pre-NDA meeting with the FDA this summer and aims to file for U.S. approval in the second half of 2026. No FDA-approved therapies currently exist for this rare liver disease. The post Mirum Stock Jumps After Voli…

Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis

Statistically significant and clinically meaningful 2.72 point reduction from baseline and 1.64 point placebo-adjusted (p=